Operator
Hello, everyone. Thank you for joining us, and welcome to Xeris Biopharma Third Quarter 2026 Earnings Conference Call. [Operator Instructions]
I will now hand the conference over to Cristi Barnett, Vice President of Investor Relations. Please go ahead.
Cristi Barnett
Vice President of Investor Relations
Thank you, Bella. Good morning, everyone, and welcome to Xeris Biopharma’s Third Quarter 2026 Financial Results Conference Call. Earlier this morning, we issued a press release detailing our third quarter 2026 financial and operating results. This press release can be found on our website at xerispharma.com. Joining me on today’s call are John Shannon, our Chairman and Chief Executive Officer; and Steve Pieper, our Chief Financial Officer. Following our prepared remarks, we will open the call for your questions.
Before we begin, I’d like to remind you that today’s discussion will include forward-looking statements regarding Xeris’ future expectations, plans, strategies, objectives and financial performance, including our full year 2026 financial guidance and our 2030 outlook. These forward-looking statements are based on management’s current assumptions and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied. For a discussion of these risks and uncertainties, please refer to the risk factors described in our filings with the SEC, including our most recent annual report on Form 10-K and our subsequent filings with the SEC as well as
